| 1 |
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia P. Corrales, Laura Hix Glickman, Sarah M. McWhirter et al. · Cell Reports
Open access |
May 2015 |
1,558 |
| 2 |
TOX is a critical regulator of tumour-specific T cell differentiation
Andrew Scott et al. · Nature
Open access |
17 Jun 2019 |
1,150 |
| 3 |
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Mary Philip, Lauren Fairchild, Liping Laura Sun et al. · Nature
Open access |
May 2017 |
955 |
| 4 |
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al. · Journal of Clinical Oncology
Open access |
29 May 2018 |
800 |
| 5 |
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
Andrea Schietinger, Mary Philip, Varintra E. Krisnawan et al. · Immunity
Open access |
Aug 2016 |
751 |
| 6 |
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Juan Ling Fu, David B. Kanne, Meredith L.L. Leong et al. · Science Translational Medicine
Open access |
15 Apr 2015 |
713 |
| 7 |
The host STING pathway at the interface of cancer and immunity
Leticia P. Corrales, Sarah M. McWhirter, Thomas Walter Dubensky et al. · Journal of Clinical Investigation
Open access |
Jul 2016 |
501 |
| 8 |
Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
Kelsey E. Sivick et al. · Cell Reports
Open access |
Dec 2018 |
452 |
| 9 |
SLC19A1 transports immunoreactive cyclic dinucleotides
Rutger David Luteijn, Shivam A. Zaver, Benjamin G. Gowen et al. · Nature
Open access |
11 Sep 2019 |
398 |
| 10 |
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Funda Meric‐Bernstam, Randy F. Sweis, Frank Stephen Hodi et al. · Clinical Cancer Research
Open access |
28 Oct 2021 |
388 |
| 11 |
A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
Dung Thi Le et al. · Clinical Cancer Research
Open access |
6 Dec 2011 |
372 |
| 12 |
Optimized arylomycins are a new class of Gram-negative antibiotics
Peter A. Smith et al. · Nature
|
Sep 2018 |
369 |
| 13 |
Listeria monocytogenes Triggers AIM2-Mediated Pyroptosis upon Infrequent Bacteriolysis in the Macrophage Cytosol
John‐Demian Sauer, Chelsea E. Witte, Jason Zemansky et al. · Cell Host & Microbe
Open access |
23 Apr 2010 |
322 |
| 14 |
Glutathione activates virulence gene expression of an intracellular pathogen
Michelle L. Reniere, Aaron T. Whiteley, Keri L. Hamilton et al. · Nature
Open access |
2015 |
297 |
| 15 |
NK cells mediate clearance of CD8 + T cell–resistant tumors in response to STING agonists
Christopher J. Nicolai, Natalie K. Wolf, I-Chang Chang et al. · Science Immunology
Open access |
13 Mar 2020 |
274 |
| 16 |
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Dung Thi Le et al. · Clinical Cancer Research
Open access |
24 May 2019 |
266 |
| 17 |
An autoimmune stem-like CD8 T cell population drives type 1 diabetes
Sofia V. Gearty, Friederike Dündar, Paul Zumbo et al. · Nature
Open access |
30 Nov 2021 |
263 |
| 18 |
Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors
Jason R. Baird, David J. Friedman, Benjamin Cottam et al. · Cancer Research
Open access |
13 Nov 2015 |
256 |
| 19 |
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric‐Bernstam et al. · Clinical Cancer Research
Open access |
25 Oct 2022 |
254 |
| 20 |
Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition
Bram Priem et al. · Cell
Open access |
Oct 2020 |
218 |
| 21 |
Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation
Lillian B. Cohn, Bithi Chatterjee, Filipp Esselborn et al. · The Journal of Experimental Medicine
Open access |
8 Apr 2013 |
194 |
| 22 |
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer
Se Hoon Park, Caroline J. Breitbach, Jeeyun Lee et al. · Molecular Therapy
Open access |
15 Jun 2015 |
185 |
| 23 |
STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia
Emily K. Curran, Xiufen Chen, Leticia P. Corrales et al. · Cell Reports
Open access |
Jun 2016 |
178 |
| 24 |
Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants
Thomas Walter Dubensky, David B. Kanne, Meredith L.L. Leong · Therapeutic Advances in Vaccines
Open access |
5 Sep 2013 |
177 |
| 25 |
Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer
Heather L. Kinkead, Alexander C. Hopkins, Eric R. Lutz et al. · JCI Insight
Open access |
17 Oct 2018 |
165 |
| 26 |
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer
Takahiro Tsujikawa et al. · Clinical Cancer Research
Open access |
9 Apr 2020 |
156 |
| 27 |
A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Jeremy B. Foote, Marleen Kok, James M. Leatherman et al. · Cancer Immunology Research
Open access |
8 May 2017 |
151 |
| 28 |
Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA
Leticia P. Corrales, Seng‐Ryong Woo, Jason B. Williams et al. · The Journal of Immunology
Open access |
Mar 2016 |
149 |
| 29 |
A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice
Bridget P. Keenan, Yvonne M. Saenger, Michel I. Kafrouni et al. · Gastroenterology
Open access |
7 Mar 2014 |
149 |
| 30 |
Foetal bovine serum influence on in vitro extracellular vesicle analyses
Brandon M. Lehrich, Yaxuan Liang, Massimo S. Fiandaca · Journal of Extracellular Vesicles
Open access |
2021 |
146 |
| 31 |
GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop
Roger A. Barker et al. · Journal of Parkinson s Disease
Open access |
3 Jun 2020 |
140 |
| 32 |
Listeria monocytogenes engineered to activate the Nlrc4 inflammasome are severely attenuated and are poor inducers of protective immunity
John‐Demian Sauer, Sabine Pereyre, Kristina A. Archer et al. · Proceedings of the National Academy of Sciences
Open access |
11 Jul 2011 |
139 |
| 33 |
Innate immune mediators in cancer: between defense and resistance
Pedro Berraondo, Luna Minute, Daniel Ajona et al. · Immunological Reviews
Review |
26 Oct 2016 |
138 |
| 34 |
STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection
Erik S. Van Dis, Kimberly M. Sogi, Chris S. Rae et al. · Cell Reports
Open access |
May 2018 |
136 |
| 35 |
Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma
Raffit Hassan, Evan W. Alley, Hedy Lee Kindler et al. · Clinical Cancer Research
Open access |
Jul 2019 |
130 |
| 36 |
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
Shuyu Huang, Sander M. J. van Duijnhoven, Alice J.A.M. Sijts et al. · Journal of Cancer Research and Clinical Oncology
Open access |
28 Sep 2020 |
116 |
| 37 |
A Macrophage Colony-Stimulating-Factor-Producing γδ T Cell Subset Prevents Malarial Parasitemic Recurrence
Murad R. Mamedov, Anja Scholzen, Ramesh V. Nair et al. · Immunity
Open access |
Feb 2018 |
105 |
| 38 |
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update
Neelima Denduluri, Mark R. Somerfield, Mariana Chávez‐MacGregor et al. · Journal of Clinical Oncology
|
20 Oct 2020 |
104 |
| 39 |
Dynamic Imaging of the Effector Immune Response to Listeria Infection In Vivo
Janelle C. Waite, Ingrid M. Leiner, Peter E. Lauer et al. · PLoS Pathogens
Open access |
24 Mar 2011 |
100 |
| 40 |
Invasive Extravillous Trophoblasts Restrict Intracellular Growth and Spread of Listeria monocytogenes
Varvara B. Zeldovich, Jennifer R. Robbins, Mirhan Kapidzic et al. · PLoS Pathogens
Open access |
3 Mar 2011 |
95 |
| 41 |
Nucleic Acid Sensors as Therapeutic Targets for Human Disease
Sarah M. McWhirter, Caroline Anne Jefferies · Immunity
Open access |
Jul 2020 |
93 |
| 42 |
Recombinant Listeria promotes tumor rejection by CD8 + T cell-dependent remodeling of the tumor microenvironment
Weiwen Deng, Victor Lira, Thomas E. Hudson et al. · Proceedings of the National Academy of Sciences
Open access |
23 Jul 2018 |
90 |
| 43 |
TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors
Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien et al. · Cancer Immunology Research
Open access |
22 Feb 2018 |
85 |
| 44 |
AttenuatedListeria monocytogenesreprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis
Patrick Hall Lizotte, Jason R. Baird, Cynthia A. Stevens et al. · OncoImmunology
Open access |
May 2014 |
84 |
| 45 |
Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Christopher Mitchell Jackson, Christina M. Kochel, Christopher J. Nirschl et al. · Clinical Cancer Research
Open access |
22 Oct 2015 |
80 |
| 46 |
Activation of human STING by a molecular glue-like compound
Jie Li et al. · Nature Chemical Biology
Open access |
12 Oct 2023 |
77 |
| 47 |
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
Erik Voets, Marc Paradé, D. Lutje Hulsik et al. · Journal for ImmunoTherapy of Cancer
Open access |
Dec 2019 |
71 |
| 48 |
Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies
Victoria M. Kim, Alex B. Blair, Peter E. Lauer et al. · Journal for ImmunoTherapy of Cancer
Open access |
22 May 2019 |
71 |
| 49 |
Clinical Development of Listeria monocytogenes–Based Immunotherapies
Dung Thi Le, Thomas Walter Dubensky, Dirk G. Brockstedt · Seminars in Oncology
Open access |
14 May 2012 |
65 |
| 50 |
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae – Identification of LYS228
Folkert Reck et al. · Bioorganic & Medicinal Chemistry Letters
Open access |
4 Jan 2018 |
59 |